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Objective: To continue evaluation of the long-term efficacy and safety of eteplirsen, a phosphorodiamidate morpho-
lino oligomer designed to skip DMD exon 51 in patients with Duchenne muscular dystrophy (DMD). Three-year pro-
gression of eteplirsen-treated patients was compared to matched historical controls (HC).
Methods: Ambulatory DMD patients who were 7 years old and amenable to exon 51 skipping were randomized to
eteplirsen (30/50mg/kg) or placebo for 24 weeks. Thereafter, all received eteplirsen on an open-label basis. The pri-
mary functional assessment in this study was the 6-Minute Walk Test (6MWT). Respiratory muscle function was
assessed by pulmonary function testing (PFT). Longitudinal natural history data were used for comparative analysis of
6MWT performance at baseline and months 12, 24, and 36. Patients were matched to the eteplirsen group based on
age, corticosteroid use, and genotype.
Results: At 36 months, eteplirsen-treated patients (n 5 12) demonstrated a statistically significant advantage of
151m (p < 0.01) on 6MWT and experienced a lower incidence of loss of ambulation in comparison to matched HC
(n 5 13) amenable to exon 51 skipping. PFT results remained relatively stable in eteplirsen-treated patients. Ete-
plirsen was well tolerated. Analysis of HC confirmed the previously observed change in disease trajectory at age 7
years, and more severe progression was observed in patients with mutations amenable to exon skipping than in
those not amenable. The subset of patients amenable to exon 51 skipping showed a more severe disease course
than those amenable to any exon skipping.
Interpretation: Over 3 years of follow-up, eteplirsen-treated patients showed a slower rate of decline in ambulation
assessed by 6MWT compared to untreated matched HC.
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This paper reports on results of continuous, 3-yeartreatment of Duchenne muscular dystrophy (DMD)
patients with eteplirsen, a 30-nucleotide-long phosphoro-
diamidate morpholino oligomer (PMO) that induces
skipping of exon 51 in DMD pre-mRNA. The etiology
of this rare but devastating disease, the eteplirsen mode
of action, and the course of the clinical studies (studies
201/202) have been described in detail in an earlier pub-
lication1 and in several reviews.2–4 Briefly, DMD is
caused by deletions and other mutations in the dystro-
phin (also known as DMD) gene that abrogate the
mRNA reading frame and prevent expression of dystro-
phin protein. As a result, affected newborn boys experi-
ence severe, progressive neuromuscular impairment
starting in early childhood,5 typically lose ambulation in
their midteens, and succumb to respiratory failure or car-
diomyopathy by their mid-20s.3,6–8 Eteplirsen-induced
skipping of exon 51 restores the mRNA reading frame,
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allowing production of an internally deleted but func-
tional dystrophin protein. This is supported by the find-
ing that internally deleted dystrophin proteins occur in
patients with Becker muscular dystrophy, a dystrophinop-
athy allelic to DMD, but with a less severe phenotype.9
The ability of eteplirsen to induce expression of dystro-
phin in DMD patients was demonstrated by an observed
increase of dystrophin-positive fibers in skeletal muscle,
observed increases in dystrophin intensity in this1 and
other studies,10,11 and by the observed restoration of the
dystroglycan complex, as evidenced by localization of
neuronal nitric oxide synthase and B-dystroglycan to the
sarcolemma.12
The ability of eteplirsen to confer clinical benefit in
study 201, a randomized, placebo-controlled study, and
study 202, its ongoing open-label extension, was primar-
ily evaluated by the 6-Minute Walk Test (6MWT). The
6MWT is an ambulatory outcome measure that has been
utilized in clinical trials for 3 DMD therapeutics (ete-
plirsen, drisapersen, and ataluren) and has been shown to
be accurate and reproducible.13 Understanding of DMD
disease progression as measured by 6MWT has increased
in recent years with publications of natural history
data14–19 as well as placebo-arm reporting from DMD
trials.20–22 Published data support that on average,
6MWT distance is stable or increases in patients
<7 years of age, whereas it declines in older
patients.15,17,18,23,24 Evidence also suggests that DMD
genotype may influence disease severity.25
Given that there is no control group in the open
label, long-term extension study, eteplirsen’s effect on dis-
ease progression as measured by 6MWT was evaluated by
comparison to matched historical controls from 2 DMD
natural history cohorts: the Leuven Neuromuscular Ref-
erence Center (LNMRC) and the Italian Telethon regis-
try.15,26 These 2 investigator-initiated studies are the only
DMD natural history data sets that have prospectively
and consistently collected 6MWT assessments for a sub-
stantial number of patients for 36 months or longer.
Comparability to the eteplirsen data set is supported by
equivalent requirements across the studies for genetic
confirmation of DMD diagnosis, patient care according
to the same international treatment guidelines for
TABLE 1. Baseline Demography
Demographic All Patients, N 5 12
Age, yr
Mean (SD) 9.3 (1.22)
Median 9.7
Min, Max 7, 11
Height, cm
Mean (SD) 123.7 (8.40)
Min, Max 116, 138
Weight, kg
Mean (SD) 31.52 (6.411)
Min, Max 22.1, 39.8
Time since DMD diagnosis, mo
Mean (SD) 56.4 (26.40)
Median 57.0
Min, Max 18, 112
Age, height, weight, and time since diagnosis are shown for
the 12 eteplirsen-treated patients at baseline.
Max 5 maximum; Min 5 minimum; SD 5 standard
deviation.
TABLE 2. Baseline and Month 36 Disease
Characteristics
All Patients, N 5 12




SD (SE) 42.19 (12.18) 151.74 (43.80)




SD (SE) 29.98 (8.65) 20.53 (5.93)




SD (SE) 34.80 (10.04) 20.02 (5.78)
Min, Max 37, 147 41, 99
6MWT distance and percentage of predicted MIP/MEP are
shown for eteplirsen-treated patients at baseline and month
36.
aBased on day 1 distance when there were 2 consecutive
days of testing.
6MWT 5 6-Minute Walk Test; Max 5 maximum;
MEP 5 maximum expiratory pressure; Min 5 minimum;
MIP 5 maximum inspiratory pressure; SD 5 standard
deviation; SE 5 standard error.
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DMD,27,28 6MWT administration following generally
accepted standards,13,29,30 and exclusion of patients with
cognitive impairment that could interfere with test adher-
ence. Patient-level data from the registries were pooled,
and analysis was performed to evaluate impact of geno-
type on disease natural history as well as to compare an
appropriately matched historical control group to
eteplirsen-treated patients.
The ability of eteplirsen to confer clinical benefit
was secondarily evaluated by pulmonary function testing.
Because long-term matched patient-level natural history
data were not available, eteplirsen-treated patients were
compared to published data31,32 in a DMD population.
Patients and Methods
Patients
Eteplirsen studies 4658-201/202 were approved by the relevant
institutional review boards prior to implementation, and
informed consent/assent was obtained from each subject and
family prior to enrollment. Patients eligible for this study were
7 to 13 years old, were able to walk 180 to 440m on the
6MWT, had confirmed out-of-frame dystrophin deletion muta-
tions amenable to exon 51 skipping, and were on stable cortico-
steroid therapy for 24 weeks (Tables 1 and 2).
Study Design
As described previously,1 patients were randomly assigned to 3
cohorts (n 5 4 each) in a double-blind fashion and received
weekly intravenous (IV) eteplirsen 30mg/kg or 50mg/kg or pla-
cebo for 24 weeks (Fig 1). Thereafter, patients who had
received eteplirsen continued at the same dose on an open-label
basis, whereas those patients who had received placebo were
randomized 1:1 to weekly 30mg/kg or 50mg/kg eteplirsen on
an open-label basis.
All infusions and assessments were performed at Nation-
wide Children’s Hospital through the double-blind phase and
thereafter until a study site geographically closer to the patient
was initiated. Collections of adverse events, concomitant medi-
cation, vital signs, weight, and laboratory assessments were per-
formed at these sites. All functional assessments continued to
be performed at Nationwide Children’s Hospital by the same
evaluators to ensure consistency.
Evaluations
All functional measures were assessed at least semiannually. The
6MWT33 was administered once, or twice on consecutive days,
according to predetermined schedules outlined in the protocol,
with each patient following the same schedule. When the
6MWT was administered on 2 consecutive days, the day 1
results were used for this analysis for comparison to matched
controls who had 1 value for each time point. Pulmonary func-
tion testing (PFT) was performed at each functional assessment
FIGURE 1: Study design: 4658-201 and 4658-202. Twelve patients with Duchenne muscular dystrophy were randomly assigned
to 1 of 3 cohorts receiving weekly intravenous (IV) infusions in a 24-week, double-blind, placebo-controlled study (study 201):
eteplirsen 30mg/kg (solid line), eteplirsen 50mg/kg (dashed line), or placebo (dotted line). At week 25, eteplirsen-treated
patients continued the same weekly dose open-label and placebo patients were randomized to open-label treatment with ete-
plirsen 30mg/kg or 50mg/kg weekly IV (study 202). Functional clinical assessments including the 6-Minute Walk Test and pul-
monary function tests were performed at each week shown on the time axis. Muscle biopsies for evaluation of dystrophin
were obtained from the upper arm at the time points specified; data reported elsewhere.1 BL 5 baseline.
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visit and included maximum inspiratory pressure (MIP), maxi-
mum expiratory pressure (MEP), and forced vital capacity
(FVC). Up to 5 efforts were allowed, and the best effort results
were used for analysis. Results were converted to percentage of
predicted values employing the widely used methodologies of
Wilson et al34 for MIP and MEP and Polgar and Varuni35 for
FVC.
Safety Assessments
Safety assessments included adverse event monitoring and clini-
cal laboratory evaluation with special emphasis on events com-
monly observed with other oligonucleotide therapeutics such as
inflammatory events, coagulopathies, and hepatic and renal tox-
icity. Safety laboratory assessments were performed at scheduled
visits, and adverse events were continuously monitored.
Patients’ Natural History Data
Patient-level historical control data were provided by E.M. on
behalf of the Italian DMD Registry database,26 and N.G.15
The Italian DMD Registry includes patient data from 11
neuromuscular care centers in Italy (Catholic University of
Rome, Rome; University of Messina, Messina; Infant Jesus
Hospital, Rome; Mondino Institute, Pavia; Gaslini Institute,
Genoa; Besta Institute, Milan; Stella Maris Institute, Pisa;
Greater Hospital, Bologna; University of Naples, Naples; Uni-
versity of Turin, Turin; University of Padua, Padua; University
of Milan, Milan). The patients in N.G.’s registry attended
LNMRC for clinical care and management.
All patients in the 2 investigator-initiated studies (histori-
cal control group) had a genetically confirmed diagnosis of
DMD and met predefined entry criteria.25,30 All eligible
patients visiting the participating centers during the enrollment
period were enrolled, supporting that the population analyzed
represented an appropriate and unbiased control cohort of
DMD patients.
The historical control group included a total of 186
patients. For the purpose of the current analysis, only patients
with corticosteroid therapy at baseline who had a baseline and
at least 1 postbaseline assessment were included (n 5 116),
that is, 87 of 97 patients from the Italian DMD Registry and
29 of 89 patients from LNMRC (Fig 2).
Clinical Assessments
The 6MWT was performed by specifically trained physiothera-
pists according to accepted clinical standards.19 Assessments
were done annually for the Italian DMD Registry, and at rou-
tine clinical visits in the LNMRC study.
Statistical Analysis
Analyses were based on 6MWT results at baseline and months
12, 24, and 36 (discrete months). Most but not all individuals
had results reported through month 36. Distance walked was
set to 0m when a patient became nonambulant. There were no
other data imputations performed for 6MWT data.
All analyses were performed on patients in the eteplirsen
intent-to-treat (n 5 12) population. The data for both
FIGURE 2: Subgroup identification. The hierarchical chart shows the predefined filters by which patients were evaluated to
select the most appropriate subgroups for comparison, as well as the most appropriate matched cohorts for comparison to
eteplirsen-treated patients. 6MWT 5 6-Minute Walk Test.
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eteplirsen dose groups are pooled throughout this report. For
all analyses, the data for the placebo to eteplirsen patients (n 5
4) while on placebo for the first 24 weeks in studies 4658-201/
202 were excluded to enable comparison of the on-treatment
time period. As such, for these 4 patients the baseline data are
equivalent to week 24, and months 12, 24, and 36 data are
equivalent to weeks 74, 120, and 168, respectively. Day 1
6MWT results were used when the test was assessed on 2 con-
secutive days.
For historical control data, if a clinic’s protocol did not
specify a baseline and/or visit frequency, the first visit for eligi-
ble patients was termed the baseline visit, and if no assessment
was available at the discrete time points, an assessment within
3.5 months of the corresponding discrete month was used.
Historical control data were evaluated for eligibility based
on the criteria outlined in Figure 2. Key parameters examined
to enable a robust statistical comparison to eteplirsen-treated
patients were (1) corticosteroid use, (2) existence of sufficient
longitudinal data to allow for identification of a baseline visit
and follow-up values, (3) age <7 or 7 years, and (4) genotype
and type of therapy to which patient is amenable. The assess-
ment of eligibility and identification of subgroups were carried
out programmatically by applying the same algorithm to
all patients. The following subgroups are presented for compar-
ative 6MWT analyses (Table 3): (1) amenable to any exon skip-
ping and <7 years old (n 5 17), (2) amenable to any
exon skipping and 7 years old (n 5 50), (3) not amenable to
exon skipping and 7 years old (n 5 41), (4) amenable to
exon 51 skipping and 7 years old (n 5 13), and (5) amenable
to other exon skipping (nonexon 51) and 7 years old (n 5
37). The subgroup that most closely matched the eteplirsen-
treated patients was amenable to exon 51 skipping and 7
years old (n 5 13).
In the comparison of eteplirsen-treated patients to histori-
cal controls, observed 6MWT data at baseline and months 12,
24, and 36 were used, and mean 6 standard error of the mean
was plotted over time for both groups (eg, eteplirsen-treated
and historical controls), and was compared using the analysis of
covariance (ANCOVA) model with group (eg, genotype, age,
eteplirsen vs untreated, etc) as a fixed-effect term and baseline
6MWT as a covariate. No adjustments were made for multiple
comparisons. In addition, change from baseline in 6MWT was
summarized for months 12, 24, and 36, and as a sensitivity
analysis, compared between the 2 groups using the Wilcoxon
rank sum test. Finally, sensitivity analysis by last observation
carried forward (LOCF) was performed.
Results
Selection of Matched Historical Control Cohort
CORTICOSTEROID TREATMENT. Based on the docu-
mented effect of corticosteroids on disease progression,3
only patients treated with corticosteroids were included
in the current analyses.
DISEASE PROGRESSION BY MUTATION TYPE AND
AGE (<7 VS 7 YEARS OLD). It has been previously
suggested that disease severity may be affected by muta-
tion type,25 and multiple publications have demonstrated
an age-dependent change in disease trajectory, showing
that when younger than 7 years, boys with DMD















skipping, <7 years old
17 5.97 (0.687) 380.8 (64.75) 17 396.2 (90.96)
Amenable to exon
skipping, 7 years old
50 9.68 (1.523) 355.7 (87.28) 47 175.7 (165.06)
Not amenable to exon
skipping, 7 years old
41 8.98 (2.019) 383.2 (89.79) 36 289.4 (194.08)
Amenable to other exon
skipping [non-51],
7 years old
37 9.76 (1.558) 355.0 (94.24) 36 199.3 (167.48)
Amenable to exon 51
skipping, 7 years old
13 9.45 (1.454) 357.6 (66.75) 11 98.5 (136.28)
Eteplirsen-treated [ITT] 12 9.41 (1.183) 363.2 (42.19) 12 263.1 (151.74)
Age and 6MWT distance at baseline and month 36 are shown for both eteplirsen-treated and historical control groups in reported
comparative analyses.
6MWT 5 6-Minute Walk Test; ITT 5 intent-to-treat; SD 5 standard deviation.
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experience a steady increase in 6MWT distance, whereas
boys aged 7 years experience progressive decline.15,26 In
the current study, the pooled historical control data set
was analyzed to further elucidate the effect of mutation
type and age on disease progression to further the field’s
understanding of DMD disease progression and to
FIGURE 3: Historical control longitudinal 6-minute walk distance over 3 years (mean 6 standard error of the mean). (A) Age dichot-
omy predicts a change in disease trajectory at age 7 years. Disease progression trajectory is shown for steroid-treated Duchenne
muscular dystrophy historical controls who were older and younger than 7 years and amenable to skipping any exon. (B) 6-Minute
Walk Test (6MWT) performance declines more rapidly in patients with mutations amenable to exon skipping compared to those
not amenable to exon skipping. Disease progression trajectory is compared in steroid-treated patients 7 years of age with geno-
types amenable or not amenable to exon skipping therapy. (C) 6MWT performance declines more rapidly in patients amenable to
exon 51 skipping versus patients amenable to skipping other exons. Disease progression trajectory is shown in steroid-treated
patients 7 years of age with genotypes amenable to exon 51 skipping or amenable to skipping other exons. y.o. 5 years old.
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identify the most comparable patient subset for compari-
son to the eteplirsen-treated cohort.
Age. The previously reported age dichotomy15,26
observed for the general DMD population was confirmed
for the subpopulation of patients with genotypes amenable
to exon skipping (see Fig 3A). Consistent with previous
reports, patients <7 years of age showed improvement
over the first 2 years of observation, followed by a decline
(although remaining above the baseline value by 25m)
between months 24 and 36. In contrast, the older age
group showed a disease progression trajectory characterized
by declines of 93m by 24 months, and 142m by 36
months. The difference between the 2 age groups was stat-
istically significant over the entire observation period (p <
0.05 at 12 months, p < 0.001 at 24 and 36 months).
Two patients in the older group did not contribute data at
the 36-month time point. Sensitivity analysis by LOCF,
an approach that imputes the last observed value for these
patients at the 36-month time point, showed a difference
of 187m (p < 0.001) in favor of the younger age group.
The decline of the younger group in the 3rd year
of observation demonstrates internal consistency of the
data as the patients in this younger population become
older (reaching a mean age of 8 years by month 24) and
begin to enter the decline phase (see Fig 3A).
Given the confirmation of age dichotomy and the
older mean baseline age of eteplirsen-treated patients of 9.3
years (range 5 7–11; see Table 1), only historical control
patients 7 years old, who will therefore be in the same
decline phase of disease as the eteplirsen-treated patients,
are appropriate for consideration as a comparator group.
Genotype. Whether all patients 7 years old or only a
genotypically similar subset of these patients should be
used for comparison to the eteplirsen cohort was further
TABLE 4. Baseline Characteristics of the Eteplirsen-Treated and Matched Historical Control Groups
Characteristic Pivotal Study 6MWT Historical Control Group
Parameter Eteplirsen-treated,
study 201/202, n 5 12
Untreated, external,
exon 51 skipping, n 5 13
Male gender 100% 100%
Age, yr
Mean (SD) 9.41 (1.183) 9.45 (1.454)
Median 9.7 9.0
Minimum, maximum 7.3, 11 7.3, 11.8
Steroids, % yes 100 100
Standard of care, % yes 100 100
Ambulatory status, % yes 100 100
6MWT distance, m
Mean (SD) 363.2 (42.19) 357.6 (66.75)
Minimum, maximum 256, 416 200, 458
Genotype, exon skippable Exon 51 Exon 51
Represented exon 5-skipping
amenable deletion mutations, No.
Exons 45–50 3 3
Exons 48, 50 1 2
Exons 49, 50 5 3
Exon 50 1 2
Exon 52 2 3
Baseline comparability of the eteplirsen-treated and historical control population 7 years old and amenable to exon 51 skipping
is explored here. Populations consist of ambulatory, steroid-treated patients with similar genotypes who had received similar stand-
ards of care.
6MWT 5 6-Minute Walk Test; SD 5 standard deviation.
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analyzed. Comparison of patients 7 years old by geno-
type demonstrates that patients amenable to exon skipping
experience more severe disease progression than those who
are not (see Fig 3B), with those amenable to exon skip-
ping showing an 85m greater decrease in 6MWT distance
at 36 months that is statistically significant (p < 0.05).
FIGURE 4: Longitudinal 6-minute walk distance (mean 6 standard error of the mean) and loss of ambulation over 3 years. (A)
Eteplirsen-treated patients experience slower disease progression than matched historical controls. Disease progression trajec-
tory is shown for steroid-treated historical controls, 7 years old amenable to exon 51 skipping (n 5 13) and eteplirsen-
treated patients (n 5 12). Baseline characteristics for eteplirsen-treated patients and those of the matched historical controls
amenable to exon 51 skipping were comparable on mean age (difference of <0.1 years) and mean baseline 6-Minute Walk
Test (6MWT; difference of <6m). The distance lost on the 6MWT was 151m less over 3 years compared to historical controls
age-matched and amenable to skipping exon 51. (B) Historical control populations experience greater loss of ambulation over
a 36-month period than eteplirsen-treated patients. (C) Individual patient data showed relative stabilization over time in
eteplirsen-treated patients compared to matched historical controls. Individual performance on 6MWT in eteplirsen-treated
patients is compared to historical controls. y.o. 5 years old.
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Patients from both groups did not contribute data to all
time points, and sensitivity analysis by LOCF showed a
difference of 84m (p < 0.05) in favor of the group not
amenable to exon skipping at 36 months.
Further comparison of patients 7 years old by
genotype demonstrates that patients amenable to exon 51
skipping experience even more rapid disease progression
than patients amenable to skipping other exons. This dif-
ference is statistically significant by 36 months (see Fig
3C), with patients amenable to exon 51 skipping show-
ing a 94m greater decrease in 6MWT distance (p <
0.05). Two patients from the exon 51 amenable group
and 1 patient from the group amenable to skipping other
exons did not contribute data at all time points. Sensitiv-
ity analysis by LOCF showed a smaller but clinically
meaningful difference of 67m (p 5 0.12) in favor of the
group amenable to skipping other exons.
These analyses indicate that the historical control sub-
set of patients 7 years old amenable to exon 51 skipping
constitutes the most appropriate matched historical control
subset for comparison to the eteplirsen-treated cohort. This
comparative subset consists of 13 patients. As noted above, 2
historical control patients in this subset did not have data
available at all time-points; 1 historical control patient con-
tributed data at baseline and 12 months, a second contrib-
uted data at baseline and 12 and 24 months. The remaining
11 historical control patients contributed data at all time
points (baseline, 12, 24, and 36 months), and therefore these
11 patients were used for the final comparison at 36 months.
Comparison of 6MWT in Eteplirsen-Treated
Patients to Matched Historical Controls
BASELINE CHARACTERISTICS OF THE ETEPLIRSEN-
TREATED AND MATCHED CONTROL COHORTS.
The 12 eteplirsen-treated patients represented 5 different
genotypes amenable to exon 51 skipping: deletions of
exons 45 to 50 (n 5 3), 48 to 50 (n 5 1), 49 and 50
(n 5 5), 50 (n 5 1), and 52 (n 5 2). Their baseline
mean age was 9.4 years and mean 6MWT distance at
baseline was 363.2m (Table 4). Mean pulmonary func-
tion tests (MIP, MEP, and FVC percentage of predicted)
at baseline were within normal ranges34 (see Table 2).
The matched historical control cohort of patients
7 years of age amenable to exon 51 skipping (n 5 13)
represented deletions of exons 45 to 50 (n 5 3), 48 to
50 (n 5 2), 49 and 50 (n 5 3), 50 (n 5 2), and 52 (n
5 3). Their baseline mean age was 9.5 years and mean
6MWT distance was 357.6m (see Table 4).
COMPARISON OF AMBULATORY FUNCTION. Evalu-
. Evaluation of 6MWT results of eteplirsen-treated
patients and historical control patients 7 years of age
amenable to exon 51 skipping showed comparable base-
line 6MWT distances that diverged through the second
and third year, culminating in a 75m difference in
6MWT decline between the groups by 24 months, and a
statistically significant (p < 0.01 from both ANCOVA
and Wilcoxon rank sum test) and clinically meaningful29
difference in 6MWT decline of 151m between the
groups by 36 months (Fig 4A).
Sensitivity analysis by LOCF, imputing the 12- and
24-month values at 36 months for the 2 historical con-
trol patients who did not have 36-month values available,
showed a difference of 121m (p 5 0.028) in favor of the
eteplirsen group.
The proportion of patients who lost ambulation was
also evaluated. Over a 3-year period, eteplirsen treatment
markedly reduced loss of ambulation compared to
matched historical controls. After 3 years, 2 of 12
(16.7%) eteplirsen-treated patients lost ambulation,
FIGURE 5: Stability of respiratory muscle function as assessed by pulmonary function testing (mean 6 standard error of the
mean). Observed percentage of predicted (% Pred) maximum expiratory pressure (MEP), maximum inspiratory pressure (MIP),
and forced vital capacity (FVC) demonstrate relative stability of respiratory muscle strength in all patients over >3 years of
treatment with eteplirsen. % Pred MEP, MIP, and FVC at month 36 were 74.3, 89.5, and 91.9, respectively. BL 5 baseline.
Mendell et al: Eteplirsen in DMD
February 2016 265
compared with 6 of 13 (46.2%) historical control patients
7 years of age amenable to exon 51 skipping (see
Fig 4B).
Given the perceived variability in DMD patients
on 6MWT over time, it is important to evaluate the
extent to which individual patients may impact the over-
all results. As such, individual patient data provide an
important perspective when comparing eteplirsen patients
versus matched historical controls. Individual patient
data further detail the differences between eteplirsen-
treated patients and the group of steroid-treated natural
history controls 7 years old and amenable to exon 51
skipping (see Fig 4C).
Pulmonary Function Tests
Over 36 months of treatment, mean percentage of pre-
dicted MIP (%pMIP) declined by 2.2% (from 91.7% at
baseline to 89.5%), mean percentage of predicted MEP
(%pMEP) declined by 5.0% (79.3% to 74.3%), and
mean percentage of predicted FVC (%pFVC) declined
by 9.4% (101.3% to 91.9%; Fig 5). Pulmonary function
data were not available for the matched historical control
patients, and therefore comparison can only be made to
published natural history. Pulmonary function data from
recent natural history studies in patients with DMD sug-
gest that %pMEP and %pMIP decline at a rate of 4%
per year for patients in the age range of 6 to 19 years,





n 5 4 (%)
Eteplirsen for
24 Weeks,a
n 5 8 (%)
Eteplirsen for
144 Weeks,b
n 5 4 (%)
Eteplirsen for
168 Weeks,c
n 5 8 (%)
Procedural pain 3 (75) 4 (50) 1 (25) 6 (75)
Vomiting 0 3 (38) 2 (50) 4 (50)
Hypokalemia 2 (50) 4 (50) 0 4 (50)
Cough 2 (50) 2 (25) 1 (25) 3 (38)
Back pain 2 (50) 1 (12) 1 (25) 4 (50)
Fall 1 (25) 1 (12) 0 1 (12)
Headache 2 (50) 1 (12) 4 (100) 4 (50)
Balance disorder 0 3 (38) 0 4 (50)
Diarrhea 1 (25) 1 (12) 1 (25) 2 (25)
Contact dermatitis 0 2 (25) 0 3 (38)
Pyrexia 2 (50) 1 (12) 0 1 (12)
Hematoma 1 (25) 2 (25) 0 2 (25)
Abdominal pain 2 (50) 0 1 (25) 1 (12)
Nausea 1 (25) 1 (12) 2 (50) 1 (12)
Rhinitis 1 (25) 1 (12) 0 1 (12)
Polyuria 0 1 (12) 0 1 (12)
Muscle spasms 0 1 (12) 2 (50) 1 (12)
Musculoskeletal pain 0 1 (12) 1 (25) 1 (12)
Proteinuria 1 (25) 0 1 (25) 5 (62)
Injection site pain 0 1 (12) 0 1 (12)
Events commonly observed in study 201/202 are reported. Events reported through 24 weeks represent those observed in the
placebo-controlled phase, whereas those reported through 144 or 168 weeks represent those observed while patients were on ete-
plirsen treatment.
aDouble-blind treatment period for the continuous eteplirsen cohort and placebo/delayed cohort.
bOpen-label treatment period for the placebo/delayed cohort.
cDouble-blind and open-label treatment periods for the continuous eteplirsen cohort.
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and %pFVC declines at a rate of 5% per year for
patients in the age range of 5 to 24 years.3,31 Thus, over
a period of 36 months, patients not receiving eteplirsen
might be expected to show declines in MEP and MIP of
approximately 11.5% and declines in FVC of approxi-
mately 14.3%.
Safety
Over approximately 3 years, weekly eteplirsen infusions
were well tolerated, with no reports of systemic reactions
and no serious adverse events related to treatment. The
most frequently reported adverse events on eteplirsen
over 3 years of evaluation were headaches (n 5 8), pro-
cedural pain related to biopsy and catheter placement (n
5 7), and proteinuria (n 5 6; Table 5). A total of 8
adverse events (7 while receiving eteplirsen, 1 on placebo)
occurring in 7 subjects were considered to be possibly or
probably related to study drug by the investigator. Treat-
ment continued uninterrupted through these events,
which involved 2 patients whose tunneled port catheters
were observed to be thrombosed prior to study drug
infusion; 1 placebo patient with mild nausea; 1 patient
with 2 events of mild erythema (reddened cheeks); 1
patient with a previous history of low white blood cell
counts whose count fell to 3.70 3 109/l (lower limit of
normal range 5 4.00 3 109/l); and 2 patients with
mild, transient proteinuria.
Protein was detected in 19 of 609 urine samples
tested over the approximate 3-year period in all patients
who received eteplirsen. All levels were low (11 on dip-
stick assay) except 2 instances of 21 that were accompa-
nied by bacteriuria; all increases were transient and
resolved spontaneously with no indication of renal toxic-
ity assessed by elevated KIM-1 or cystatin C, or clinical
signs or symptoms. An episode of proteinuria, which was
determined to be unrelated to the study treatment, also
occurred in 1 patient on placebo. Like the other episodes
of proteinuria, this episode was mild, and required no
pharmacologic intervention or interruption of study
treatment. Hematology and coagulation parameters were
generally within normal range. Blood chemistry reflected
the expected disease-related abnormalities, with markedly
elevated creatine kinase, aspartate aminotransferase, and
alanine aminotransferase, all of which decreased over the
course of treatment with eteplirsen. There were no signs
or symptoms of hepatic toxicity.
None of the adverse events led to treatment inter-
ruption or dose adjustments. All patients continued to be
treated with the assigned dose of eteplirsen, and there
were no deaths or treatment discontinuations.
Discussion
Eteplirsen has been previously demonstrated to reliably
induce the production of functional dystrophin in
patients with DMD,1,10–12 and in so doing, significantly
slowed the rate of progression of this devastating disease
as demonstrated here by comparison of longitudinal
6MWT results to untreated, matched historical controls
over 36 months. This was evidenced by a slower decline
in walking ability in eteplirsen-treated patients compared
to age-matched historical controls amenable to exon 51
skipping, with a clinically relevant 75m difference by 24
months, and a statistically significant and clinically rele-
vant difference of 151m by 36 months.
Because 2 historical control patients did not have
data available at the 36-month time point (1 patient con-
tributed data at baseline and 12 months, whereas the sec-
ond contributed data at baseline and 12 and 24
months), sensitivity analysis was conducted by LOCF. In
this approach, the last observed value for the first patient
at 12 months (375m) and for the second patient at 24
months (320m) was imputed as a 36-month result. This
is an extremely conservative approach, as neither patient
would be expected to remain stable over such a long
period of time given their respective ages at baseline (8.6
years and 11.5 years, respectively) and last reported
6MWT distances. Even using this very conservative
approach, the analysis favored the eteplirsen group by
121m, a difference that is clinically meaningful and stat-
istically significant.
Not only did eteplirsen-treated patients experience
a slower decline in 6MWT distance, fewer eteplirsen-
treated patients lost ambulation than untreated, matched
historical controls. During the 3-year treatment period, 2
of 12 eteplirsen-treated patients lost ambulation by year
1 and none thereafter (16.6%). In contrast, 6 of 13
(46%) historical control patients lost ambulation by 36
months.
To validate the approach for selecting the natural
history control cohort, it was essential to ensure compa-
rability of the cohort to eteplirsen-treated patients at
baseline as well as comparability of their expected rates
of disease progression. The overall historical control
cohort used was considered a valid comparator group
based on the following: (1) all patients who met the pre-
defined entry criteria and visited the participating centers
during the enrollment period were included in the histor-
ical control studies, supporting that the population
enrolled represents an unbiased control cohort of DMD
patients; (2) patients with cognitive impairment that
could impact 6MWT outcome were excluded from all
studies; (3) the participating clinics specialize in
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neuromuscular care and follow the internationally recog-
nized treatment guidelines for patients with DMD27,28
that is used for the eteplirsen-treated patients, including
recommendation for corticosteroid use, dose, and dose
adjustment; (4) assessments of the 6MWT were per-
formed by specifically trained physiotherapists according
to the same established standards used for the eteplirsen-
treated patients.13 To further increase comparability
between the groups not only at baseline but also by rate
of disease progression, control patients were matched to
the eteplirsen population based on (5) corticosteroid use,
(6) age, and (7) genotype.
Selection based on these parameters is supported by
recent reports indicating that the main variables impact-
ing disease progression in ambulatory DMD patients as
measured by 6MWT are age, genotype, 6MWT distance
at baseline, and corticosteroid use.3,16,24,25,29 Given the
data that support the effect of corticosteroid therapy on
delaying disease progression in DMD,3 corticosteroid use
at baseline was required for all patients in the eteplirsen-
treated as well as the control cohort.
Results of these analyses have important implica-
tions for the field’s understanding of disease natural his-
tory as well as for clinical trial design. Confirmation of
the previously reported age dichotomy for the subset of
steroid-treated patients amenable to exon skipping, show-
ing a rapid and consistent decline in ambulation, endur-
ance, and muscle function as measured by the 6MWT in
boys with DMD who are 7 years of age, whereas those
<7 years old are stable or increase in their 6MWT dis-
tance, supports the exclusion of patients <7 years old
from studies that aim to prognostically enrich for a
declining population.
Earlier analysis of the Italian DMD registry had
suggested the potential for mutation type to affect disease
progression.25 In the current analysis, patients amenable
to exon skipping were shown to experience more rapid
declines on 6MWT than those with mutations not ame-
nable to exon skipping, a difference that was statistically
significant at 36 months. Furthermore, patients amenable
to exon 51 skipping experienced an even more rapid dis-
ease progression than patients amenable to skipping other
exons. These data are consistent with the literature and
suggest that matching placebo and treated patients by
amenability to any exon skipping may be important in
evaluating drug effect.
Of note, the mean 6MWT distance of the
eteplirsen-treated patients at 12 months was essentially
equivalent to the historical control cohort. This is most
likely due to the early loss of ambulation experienced by
2 eteplirsen-treated subjects in a small study population.
Whether this suggests that longer evaluation periods are
needed to observe a treatment effect will be explored fur-
ther in the larger, PROMOVI confirmatory study that is
currently underway.
Taken together, these analyses confirm that steroid-
treated patients 7 years old who are amenable to exon
51 skipping are the most appropriate natural history con-
trol for the eteplirsen study 4568-201/202 cohort. Fur-
thermore, these analyses confirm the validity of the
4568-201/202 eteplirsen study design, indicating that
enrolling patients 7 years old enables the sensitive eval-
uation of functional treatment effect without the con-
founding impact of data from patients <7 years old
who, although lagging behind their healthy age-matched
peers, show gains in motor function due to growth and
development. Limitations of the eteplirsen clinical study
presented here include the small number of patients as
well as the unblinded treatment of patients in the exten-
sion phase, although disease natural history suggests that
placebo effect would be unlikely to preserve ambulation
over 3 years in the advanced population studied. The
close concordance of the mean baseline 6MWT of the
eteplirsen-treated patients and the historical controls was
somewhat unexpected but may suggest that the heteroge-
neity observed for the general DMD population
decreases significantly when patients are comparable on
factors known to influence disease progression, namely
age, steroid use, baseline 6MWT, and genotype.
The 6MWT has been widely used as an outcome
measure in DMD, as it is an integrated assessment of
global muscle function and endurance. In addition, loss
of ambulation is a crucial disease milestone that carries
significant emotional as well as physical and practical
implications for patients and families, marking a transi-
tion to progressively decreasing independence and
increasing need for assistance with activities of daily
living.36–39
Although preservation of ambulation is strongly
desired, respiratory failure is a leading cause of death for
patients with DMD.36,38 The importance of respiratory
abnormalities is well understood in later stages of DMD,
but early subclinical deterioration of respiratory muscles
with a mean annual decline in %pMIP and %pMEP of
approximately 4% and %pFVC of approximately 5% has
only recently been recognized.3,31 %pMIP and %pMEP
assess progression of DMD regardless of ambulatory sta-
tus and are the most sensitive indicators of decreasing
respiratory muscle strength, with %pMEP being the first
pulmonary parameter to decline in patients with
DMD.39,40 Thus, the observed relative stability of respi-
ratory muscle function over >3 years observed in this
study is important supporting evidence for the clinical
efficacy of eteplirsen above and beyond endurance,
ANNALS of Neurology
268 Volume 79, No. 2
ambulation, and muscle function that is measured by the
6MWT.19
Eteplirsen was well tolerated over 3.2 years. Notably,
adverse events frequently seen with other RNA analogs,
including administration site reactions, flulike symptoms,
coagulopathies, inflammatory response, and renal or
hepatic toxicity,20,33 were observed rarely, if at all.20,33
This is consistent with the safety profile and tolerability of
eteplirsen and other PMO-based oligomers seen in ani-
mals41–43 and in other human studies.44 This lack of tox-
icity is attributed to PMO chemistry, which is charge-
neutral, largely unmetabolized, and not linked to immune
activation,10,45 platelet activation, or hepatotoxicity.
Outcome assessment in comparison to an appropri-
ately matched natural history or historical control popula-
tion has been used to support regulatory approval of
several therapies targeted to ultra-orphan populations over
the past decade including Myozyme for Pompe disease46
and CEPROTIN for patients with severe congenital pro-
tein C deficiency.47 These present results indicate such an
approach may also be appropriate for DMD, especially as
it would spare declining patients from receiving placebo
rather than potentially disease-altering treatment.
In summary, this analysis shows that eteplirsen-
treated patients with DMD experienced a slower decline
in disease progression over 3 years as measured by the
6MWT than historical control patients who were appro-
priately matched for age, steroid use, and mutation type.
The observed differences were clinically meaningful, statis-
tically significant, and supported by differences in the rate
of loss of ambulation and by the relative stability seen on
pulmonary function testing over the same time period.
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